Apollo Hospitals Q1 FY27 Earnings Call: Guides 20% Hospital Revenue Growth, Digital Cash Loss Nears Break-Even (APOLLOHOSP)

Apollo Hospitals Enterprise Ltd held its Q1 FY27 earnings call on August 12, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financial Performance

• Consolidated revenue grew 21% YoY to Rs.7,043 Cr — EBITDA increased 28% to Rs.1,092 Cr, with margin expanding from 14.6% to 15.5% in Q1 FY2026-2027.
• Healthcare Services revenue Rs.3,567 Cr (+22%) — EBITDA margin of 24.2%; established hospitals delivered 25.9%, while new hospitals reported an EBITDA loss of Rs.38 Cr.
• Apollo HealthCo revenue Rs.2,977 Cr (+20%) — EBITDA improved to Rs.171 Cr versus Rs.94 Cr in Q1 FY2025-2026; digital cash loss narrowed to Rs.10 Cr, with management stating it is poised for break-even in the upcoming quarter.
• AHLL revenue Rs.499 Cr (+15%) — EBITDA margin rose to 11.8% from 9.3% YoY; diagnostics vertical grew 31%; PAT loss narrowed to Rs.1 Cr from Rs.8 Cr.
• Consolidated PAT Rs.581 Cr, +34% YoY — broad-based margin improvement across hospitals, healthco, and diagnostics segments.
• Three hospital closures in Q1 FY2026-2027 — Chennai Tondiarpet (renovation), Lavasa (land possession only, non-operational), and Bangladesh OMA (exited); management indicated no material financial impact.

Occupancy, Pricing, and Case-Mix Trends

• Inpatient volumes +13% YoY; occupancy 70% — ARPOB reached Rs.1,86,630 (+8%), driven by case complexity and robotic surgery uptake (+85%) rather than tariff hikes.
• High-acuity (Congo T) volumes +15%, revenues +24% — contributed 62% of inpatient net revenue in Q1 FY2026-2027.
• Established units IP volume growth of 11% — broad-based across regions, driven by a shift to elective and semi-elective cases; management noted this is not seasonal.
• 4% pricing growth in healthcare services — management termed it sustainable and in line with medical inflation; insurance contracts reset every two years, implying ~10% increase per reset.
• 80% of in-patients paid less than Rs.2 lakhs — 90% paid less than Rs.5 lakhs, underscoring affordability; management conducted ~100 hours of dialogue with insurers, who are supportive of inflation-linked tariff increases.
• Tamil Nadu occupancy reached 70% — management sees further growth potential from operational efficiencies and demand tailwinds.

Pharmacy, Diagnostics, Insurance, and Platform Economics

• Pharmacy and diagnostics GMB grew 25-30% — diagnostics vertical revenue +31% in Q1 FY2026-2027; pharmacy CM1 and CM2 margins turned positive, with cost-of-delivery improvements expected by Q3 FY2026-2027.
• Digital cash loss reduced to Rs.10 Cr — management expects sustainable quarterly cash expense of ~Rs.80 Cr for the digital segment; some one-time costs were incurred in Q1.
• Insurance business grew 80% on a small base — management targets break-even by Q3 FY2026-2027; operates as a corporate agent with cross-pollination from the Apollo ecosystem; no advertising spend.
• AHEL diagnostics margins achieved 14% — management targets 20% margins over the next six to eight quarters (through approximately Q3 FY2027–Q1 FY2029); diagnostics growth guided at 20%+.
• Insurance payer mix at ~85% — management stated this is maintainable even in new greenfield expansions outside southern states; no specific FY guidance was given for the mix.
• NPS Swasthya tie-up: no material impact for ~18 months — the regulator PFRDA is currently setting regulatory requirements; initial ~12 months (through ~Q2 FY2027-2028) focused on customer acquisition; 25% of pension contributions can be used for OPD or IP expenses under a top-up layer.

New Hospitals, Proton Centers, and Bed Pipeline

• 180-bed Sarjapur facility operationalised — Gurugram hospital on track for soft launch in September 2026 and full opening in October 2026; meaningful revenue contribution expected from Q3 or Q4 FY2026-2027.
• Management targets 14,100 beds by FY2030-2031 — "plan to reach 14,100 beds by FY2030-2031, funded largely from internal accruals"; funded largely from internal accruals.
• New hospital losses guided at Rs.150 Cr for FY2026-2027 — losses may temporarily increase by at least Rs.20 Cr per quarter around the Gurgaon opening, before declining; Hyderabad Financial District hospital expected to break even in Q2 FY2026-2027.
• Chennai proton center: 3-gantry unit (2 mobile, 1 fixed) — mobile gantries fully occupied with frequent waitlist; 30% of volumes from overseas patients; Delhi proton center announced (single gantry, coming online in a few years).
• Certain brownfield bed additions delayed — originally planned for FY2026-2027, pushed to FY2027-2028 and FY2028-2029 due to configuration changes at Jubilee Hills expansion and delays in finalising the lease deed for the Secunderabad project.
• Delhi Cancer Center: evaluating two location options — if developed separately, configuration could be 125 total beds with 100 census beds; initial plan assumed 100 census beds as part of an existing facility.

Government Recommendations, PFRDA, and EWS Obligations

• Government parliamentary committee recommended 3-5% of GDP healthcare spend — management cited "government's parliamentary committee recommended healthcare spending to rise to 3–5% of GDP" alongside zero-rated GST and reduced customs duties; management supported the objectives but cautioned that price controls may disincentivise private investment.
• India needs to add 2.4 million beds — management noted the gap as a structural demand driver for private-sector capacity expansion.
• Regulator PFRDA setting requirements for NPS Swasthya — "the regulator PFRDA is currently setting regulatory requirements for the product"; product very early stage with only two proofs-of-concept completed; Apollo participated in one (OPD-focused).
• EWS obligations exist in Delhi, Hyderabad, and Kolkata hospitals — most Apollo hospitals are on free-hold land, resulting in minimal EWS obligations compared to other operators; the upcoming Gurugram hospital is also on free-hold land.
• Proposed restructuring of omni-channel pharmacy and digital health business — on track for completion within FY2026-2027; mother and child business transaction concluded and being merged into a larger platform, subject to government regulatory clearance.
• No specific EWS bed count provided — management stated they will revert with exact numbers offline.

Growth Trajectory, Margin Outlook, and Strategic Priorities

• Hospital business guided at ~20% revenue growth for FY2026-2027 — established hospitals at 13-14%, with new hospitals adding ~7%; full-year established units revenue growth of 18-20%, supported by Bangladesh patient volumes normalisation (+60% in Q1 FY2026-2027).
• Established hospital margins expected to sustain and inch up over 24 months — management sees potential for further cost takeouts but is focused first on sustaining the current ~26% level through FY2028-2029.
• Recently commissioned hospital cluster targets overall break-even by Q3-Q4 FY2027-2028 — management to provide a detailed update next quarter.
• AHEL diagnostics targeting 20% margins over 6-8 quarters — through approximately Q3 FY2027–Q1 FY2029; diagnostics growth guided at 20%+; primary care grew ~12% in Q1 FY2026-2027, with plans to add clinics over the next two to three quarters.
• International patient business grew 26% in Q1 FY2026-2027 — Bangladesh volumes at 60-70% of pre-COVID peak, partially offset by higher case complexity and value; sequential IPS volume growth of 50% from Bangladesh in Q1 versus Q4 FY2025-2026.
• Strategy centered on building India's most integrated healthcare platform — management views primary care, diagnostics, digital engagement, insurance, and hospitals as interconnected journeys to improve acquisition, retention, clinical outcomes, and lifetime value; disciplined capital allocation to sustain momentum.